Hyperkalemia Treatment Market - Global Growth, Trends and Forecast (2022 - 2027) By Types, By Application, By Regions and By Key Players: AstraZeneca PLC, Ardelyx, Perrigo Company PLC, Vifor Pharma Management Ltd

The Hyperkalemia Treatment market is estimated to grow at a CAGR of 19.5% over the forecast period, from USD 640.75 million in 2021 to USD 810.20 million by 2027.

Hyperkalemia Treatment Market Overview

Hyperkalemia is a condition in which the body's potassium homeostasis is disrupted, resulting in increased serum potassium. Globally, the rise in the geriatric population is causing an increase in the prevalence of acute and chronic hyperkalemia. Because of the ageing population and developments in medical technology, the prevalence of heart failure and chronic kidney disease is expected to rise, putting a larger number of patients at risk for hyperkalemia. The number of elderly people, those aged 60 and up, is anticipated to more than double by 2050 and more than triple by 2100, according to data from the World Population Prospects: The 2017 Revision, growing from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion in 2100.

The expansion of the Hyperkalemia Drugs Market will be fueled by factors such as the rising incidence of chronic diseases, the rising use of various treatments, and the rising prevalence of hyperkalemia. However, a faulty diagnosis could stifle market expansion. The comprehensive examination of the drivers and challenges will aid in determining end goals and fine-tuning marketing tactics in order to acquire a competitive advantage.

Industry News and Updates

March 15, 2022: Sanofi announces €300 million collaboration with Blackstone Life Sciences to advance an innovative treatment for multiple myeloma--

Sanofi and Blackstone (NYSE: BX) today announced a strategic, risk-sharing collaboration under which funds managed by Blackstone Life Sciences (BXLS) will contribute up to €300 million to accelerate the global pivotal studies and the clinical development program for the subcutaneous formulation and delivery of the anti-CD38 antibody Sarclisa, to treat patients with multiple myeloma (MM). If successful, BXLS will be eligible to receive royalties on future subcutaneous sales. The pivotal study for the subcutaneous formulation is expected to begin in the second half of 2022.

What are the major Applications, Types and Regions for Hyperkalemia Treatment Market?

Market is segmented based on the type, applications, companies and regions.

By Type, it is segmented into

• Sodium Bicarbonate


• Beta2 Agonists


• Diuretics


• Others

By Application, it is segmented into

• Hospital Pharmacy


• Clinic


• Other

Hyperkalemia Treatment Market Regional Analysis

The existence of leading market players, the high frequency of disease-related illnesses, favorable healthcare legislation, and high disposable income of patients all contribute to the United States' supremacy over the forecast period. Furthermore, the rising frequency of hyperkalemia and the growing senior population are two important factors driving the market forward. As a result, the large patient population is predicted to increase the number of patients seeking treatment, which will sustain growth in the near future. For example, the federal government in the United States has been operating numerous awareness campaigns through various projects, which is likely to have a favorable impact on the industry. Hence, this increasing adoption of a patient-centric approach by healthcare payers is expected to drive the US hyperkalemia treatment market, during the forecast period.​

• North America
  
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East & Africa
  
  
  • Latin America
  
  
  
  

The Hyperkalemia Treatment Market describes the factors driving the global growth opportunities in upcoming years and highlights market channels. In addition, the report analyzes market size and share, trends, by geographic region, end-use type and segment. It focuses extensively on revealing a detailed regional analysis. The Global Hyperkalemia Treatment Market report also conducted a PESTEL analysis of the industry to study the main influencing factors and entry barriers of the industry.

What is our Hyperkalemia Treatment Market report scope?

Frequently Asked Questions

What is the growth rate of Hyperkalemia Treatment Market?

The Hyperkalemia Treatment Market is growing at a CAGR of 19.5% over the next 5 years.

Who are the key players in Hyperkalemia Treatment Market?

AstraZeneca PLC, Ardelyx, Perrigo Company PLC, Vifor Pharma Management Ltd, Sanofi SA, Relypsa Inc., Odan Laboratories Ltd, Klarvoyant Biogenics Pvt. Ltd, Concordia Pharmaceuticals Inc, Steadfast MediShield Pvt. Ltd, AdvaCare Pharma, Eli Lilly and Company, Carolina Medical Products, RSM Kilitch Pharma Pvt. Ltd, Novel Laboratories

What are the significant types of Hyperkalemia Treatment Market?

Sodium Bicarbonate, Beta2 Agonists, Diuretics, Others

What are the major end-use applications of Hyperkalemia Treatment Market?

Hospital Pharmacy, Clinic, Other

All our reports are custom made to your company needs to a certain extent, we do provide 5 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report as your needs.